'Hunger hormone' may treat severe peripheral artery disease

18-Dec-2015 - A new study by a team of researchers from New Zealand's University of Otago and Japan suggests that the appetite-regulating hormone ghrelin could be used clinically for the early treatment of critical limb ischemia (CLI), an advanced form of peripheral artery disease. CLI is the severe ...

New class of drug targets heart disease

19-Sep-2013 - Researchers at the University of Alberta have developed a synthetic peptide that could be the first in a new class of drugs to treat heart disease, high blood pressure and diabetes. Researchers at the U of A found that a deficiency in the peptide apelin is associated with heart failure, pulmonary ...

Bayer’s Riociguat submitted for regulatory approval in the U.S. and EU

12-Feb-2013 - Bayer HealthCare has submitted the oral investigational drug Riociguat to treat patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) for regulatory approval in the United States and in the European Union. “These regulatory ...

New Consortium Paves the way for Improved Treatment of Hypertension and Associated Vascular Complications

20-Nov-2009 - Top Institute Pharma has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke. ...

Key player identified in cascade that leads to hypertension-related kidney damage

09-Nov-2009 - A key player in a cascade that likely begins with stress and leads to high blood pressure and kidney damage has been identified by researchers who say the finding may lead to better ways to control both. Medical College of Georgia researchers have found endothelin, a powerful blood vessel ...

UC San Diego researchers reverse pulmonary arterial hypertension in mouse models

27-Oct-2009 - Researchers at the University of California, San Diego, have identified a key protein that promotes the development of pulmonary arterial hypertension in humans and mice. This groundbreaking discovery has implications for future drug therapies that may extend the life of patients with pulmonary ...

Bayer Strengthens Research and Development

Pharmaceutical pipeline is well filled, with 50 projects currently in phases I to III of clinical testing

16-Dec-2008 - The Bayer Group is to further expand its research and development activities despite the current financial and economic crisis. “The task now is to set the right course. Only through innovation can our company generate the growth that is essential to safeguard its sustained success,” said Werner ...

Bayer Reports Progress in Clinical Program for Riociguat - Novel approach for the treatment of pulmonary hypertension

Positive Phase II Findings Reported at European Respiratory Society Meeting / Phase III Studies to Begin in 2008

07-Oct-2008 - Based on positive Phase II trial findings, Bayer Schering Pharma will move into Phase III trials with its oral agent riociguat (BAY 63-2521). Riociguat is the first member of a new class of vasodilating agents called soluble guanylate cyclase (sGC) stimulators. It is being investigated as a new ...

VentriPoint, University of Washington Sign Research and Technology Development Agreement

Projects Focus on Completion of the Congenital Heart Disease Database and the Further Transition of Knowledge and Processes to VentriPoint for the Development of the VentriPoint Diagnostic System

05-May-2008 - VentriPoint(TM) Diagnostics Ltd. announced that it has finalized a research and technology development agreement with the University of Washington to collaborate on projects that will enhance and broaden the VentriPoint Diagnostic System (VDS) commercial offering. Under the terms of the ...

Positive study with Actelion's bosentan (Tracleer®) in CTEPH

06-Mar-2007 - Actelion Ltd announced the initial results from the double-blind, placebo-controlled, multicenter study BENEFiT (Bosentan Effects in Inoperable Forms of Chronic Thromboembolic Pulmonary Hypertension). The study met its primary objective, as treatment with bosentan (Tracleer®) was associated with ...